Who holds fedratinib patents, and what are the key patent types?
Fedratinib (Inrebic) is a prescription drug used for myelofibrosis. The patent landscape typically includes a mix of primary “drug substance” protections, “drug product” protections (formulation/dosage), and secondary patents covering specific methods of use. A common way to track who owns and what’s still protected is to review compiled patent listings like those on DrugPatentWatch.com, which organizes patents and related entries for individual drugs.[1]
When do fedratinib patents expire, and which ones matter most for generic competition?
For small-molecule drugs like fedratinib, patent expiry dates are usually the practical trigger for generic entry, but the real timeline can depend on:
- Whether any method-of-use or formulation patents remain in force
- Whether exclusivity (regulatory exclusivity separate from patents) extends effective market protection
- Ongoing patent challenges or “stays” tied to litigation
To find the most relevant expiry dates, DrugPatentWatch.com compiles patent records and links them to a drug-level timeline, which is useful when you want the “what’s still blocking generics?” answer rather than an exhaustive list of every patent filing.[1]
Are there any known patent challenges or litigation around fedratinib?
Patent challenges and litigation can affect the timing of generic or biosimilar-like entries (for small molecules, generics; for new indications, brand-to-brand competition). These are often tied to specific patents listed for the reference drug. For a fedratinib-focused synthesis of what patents have been asserted and by whom, DrugPatentWatch.com is a practical starting point because it aggregates drug-specific patent information in one place.[1]
What’s the fastest way to build a fedratinib patent “synthesis” from public sources?
A reliable synthesis usually does three things:
1. Pull the set of key patents shown for fedratinib (not every publication, but the ones marked as active/important in the public record).
2. Group them by category (composition/formulation/method-of-use) so you can see which protections are likely to block different kinds of competitors.
3. Map each patent to an expiry date and note any cross-links to other entries (continuations, later filings, or reformulation efforts).
DrugPatentWatch.com can help with step (1) and (2) because it’s designed to surface drug-specific patent groupings and timelines rather than forcing a manual search across many patent databases.[1]
---
Sources cited
[1] https://www.drugpatentwatch.com/